Background Even though pharmacists have devoted considerable time to ensuring patient safety during the process of preparing and dispensing chemotherapy, only a few studies have evaluated their efforts. Objective To evaluate the clinical and economic impact of pharmacists’ interventions in a large volume chemotherapy preparation unit. Setting A 1600-bed tertiary hospital in Seoul, Korea. Method Pharmacist intervention records from May 2012 to April 2013 were retrospectively reviewed. The clinical significance of interventions was rated by one physician and one pharmacist. A cost-benefit analysis was conducted. The benefit from interventions was estimated through both cost avoidance based on the potential to avoid an adverse drug event (ADE) and cost savings related to reducing discarded products. Cost was estimated from the pharmacists’ salary corresponding to the time spent in reviewing chemotherapy prescriptions. Main outcome measure Acceptance rate, clinical significance, net cost-benefit, and
cost-benefit ratio of pharmacist interventions. Results Among 39,649 cancer chemotherapy prescriptions in 6364 patients, 631 interventions were performed for 435 patients. The acceptance rate was 72.1 %. Most cases of declined interventions were related to dosage adjustment within the range of <10 % of the prescribed dosage. More than half of the interventions were considered as clinically more than “significant” (50.4 %). The cost-benefit analysis showed a clear cost benefit with a net cost-benefit of $116,493 and a cost-benefit ratio of 3.64:1. Conclusion Pharmacists’ interventions in a large volume ambulatory-based chemotherapy preparation unit provided a positive economic impact on health care budget and were effective in preventing clinically significant ADEs.
Chemotherapy Compounding Cost-benefit Korea Pharmacist intervention
This is a preview of subscription content, log in to check access.
No specific funding for this work was received.
Conflicts of interest
The authors have no conflicts of interest to declare.
National Cancer Information Center. Cancer facts and figures 2013 in the Republic of Korea. Goyang: National Cancer Information Center; Accessed 1 Dec 2015. http://www.cancer.go.kr.
Ranchon F, Salles G, Spath HM, Schwiertz V, Vantard N, Parat S, et al. Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer. 2011;11:478.CrossRefPubMedPubMedCentralGoogle Scholar
Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG, et al. EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther. 2015;40:196–203.CrossRefPubMedGoogle Scholar
Kohn L, Corrigan J, Donaldson M. To err is human: building a safer health system. Washington, DC: National Academies Press; 1999.Google Scholar
Voeffray M, Pannatier A, Stupp R, Fucina N, Leyvraz S, Wasserfallen JB. Effect of computerisation on the quality and safety of chemotherapy prescription. Qual Saf Health Care. 2006;15:418–21.CrossRefPubMedPubMedCentralGoogle Scholar
Sievers TD, Lagan MA, Bartel SB, Rasco C, Blanding PJ. Variation in administration of cyclophosphamide and mesna in the treatment of childhood malignancies. J Pediatr Oncol Nurs. 2001;18:37–45.CrossRefPubMedGoogle Scholar
Muller T. Typical medication errors in oncology: analysis and prevention strategies. Onkologie. 2003;26:539–44.PubMedGoogle Scholar
Phillips J, Beam S, Brinker A, Holquist C, Honig P, Lee LY, et al. Retrospective analysis of mortalities associated with medication errors. Am J Health Syst Pharm. 2001;58:1835–41.PubMedGoogle Scholar
Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. JAMA. 1997;277:307–11.CrossRefPubMedGoogle Scholar
Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64:2483–7.CrossRefPubMedGoogle Scholar
Lee AJ, Boro MS, Knapp KK, Meier JL, Korman NE. Clinical and economic outcomes of pharmacist recommendations in a veterans affairs medical center. Am J Health Syst Pharm. 2002;59:2070–7.PubMedGoogle Scholar
Bedouch P, Tessier A, Baudrant M, Labarere J, Foroni L, Calop J, et al. Computerized physician order entry system combined with on-ward pharmacist: analysis of pharmacists’ interventions. J Eval Clin Pract. 2012;18:911–8.CrossRefPubMedGoogle Scholar
Fernandez-Llamazares CM, Calleja-Hernandez MA, Manrique-Rodriguez S, Perez-Sanz C, Duran-Garcia E, Sanjurjo-Saez M. Impact of clinical pharmacist interventions in reducing paediatric prescribing errors. Arch Dis Child. 2012;97:564–8.CrossRefPubMedGoogle Scholar
Goldspiel BRDR, Daniels CE. A continuous-improvement approch for reducing the number of chemotherapy-related medication errors. Am J Health Syst Pharm. 2000;57:S4–9.PubMedGoogle Scholar
Sano HS, Waddell JA, Solimando DA Jr, Doulaveris P, Myhand R. Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract. 2005;11:21–30.CrossRefPubMedGoogle Scholar
Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich PS, et al. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs. J Oncol Pharm Pract. 2013;19:8–17.CrossRefPubMedGoogle Scholar
Dinning C, Branowicki P, O’Neill JB, Marino BL, Billett A. Chemotherapy error reduction: a multidisciplinary approach to create templated order sets. J Pediatr Oncol Nurs. 2005;22:20–30.CrossRefPubMedGoogle Scholar
Womer RB. Multidisciplinary systems approach to chemotherapy safety: rebuilding processes and holding the gains. J Clin Oncol. 2002;20:4705–12.CrossRefPubMedGoogle Scholar
Schwappach DL, Wernli M. Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl). 2010;19:285–92.CrossRefGoogle Scholar
Suzuki S, Chan A, Nomura H, Johnson PE, Endo K, Saito S. Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy. J Oncol Pharm Pract. 2015;0:1–8.Google Scholar
Overhage JM, Lukes A. Practical, reliable, comprehensive method for characterizing pharmacists’ clinical activities. Am J Health Syst Pharm. 1999;56:2444–50.PubMedGoogle Scholar
Nesbit TW, Shermock KM, Bobek MB, Capozzi DL, Flores PA, Leonard MC, et al. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health Syst Pharm. 2001;58:784–90.PubMedGoogle Scholar
Delpeuch A, Leveque D, Gourieux B, Herbrecht R. Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res. 2015;35:457–60.PubMedGoogle Scholar
Elsaid K, Truong T, Monckeberg M, McCarthy H, Butera J, Collins C. Impact of electronic chemotherapy order forms on prescribing errors at an urban medical center: results from an interrupted time-series analysis. Int J Qual Health Care. 2013;25:656–63.CrossRefPubMedGoogle Scholar
Nerich V, Limat S, Demarchi M, Borg C, Rohrlich PS, Deconinck E, et al. Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors. Int J Med Inform. 2010;79:699–706.CrossRefPubMedGoogle Scholar
Le Guen R, Madelaine I, Tournamille JF, Bellanger A, Astier A, Braguer D, et al. Study impacto: descriptive analyzis of pharmacist’s clinical practice in onco-hematology. Ann Pharm Fr. 2015;73:223–8.CrossRefPubMedGoogle Scholar